Scientific evidence

A physician’s guide to the use of gene expression profile ancillary diagnostic testing for cutaneous melanocytic neoplasms

Dec 2023

Author: Marks E, et al.

Publication: Journal of Clinical and Aesthetic Dermatology

A physician’s guide to the use of gene expression profile ancillary diagnostic testing for cutaneous melanocytic neoplasms

Dec 2023

A real-world assessment of common use scenarios of MyPath GEP testing by dermatopathologists and dermatologists to achieve definitive diagnoses and personalized patient management plans.

Author: Marks E, et al.

Publication: Journal of Clinical and Aesthetic Dermatology

Performance of the 23-gene expression profile (23-GEP) test by histopathological evaluation in an independent, multi-center performance cohort of cutaneous melanocytic neoplasms

Nov 2023

Accuracy data in an independent, multi-center cohort of 2512 melanocytic lesions

Author: Goldberg M, et al.

Publication: Skin

31-gene expression profile testing in cutaneous melanoma and survival outcomes in a population-based analysis: A SEER collaboration

Jun 2023

Study data from Castle Biosciences' collaboration with the National Cancer Institutes SEER program registries.

Author: Bailey C, et al.

Publication: JCO-PO

Abnormally pigmented lesion with uncertain malignant potential

Jun 2023

With benign GEP results, dermatopathologist adjusts diagnosis to a benign neoplasm and patient avoids re-excision.

Asymmetrical pigmented lesion with high clinical suspicion for melanoma

Jun 2023

A 27-year-old female patient was seen by a primary care physician who recommended follow-up with a dermatologist for assessment of a concerning melanocytic lesion.

Multi-colored lesion with uncertain malignant potential

Jun 2023

Conflicting clinical and histopathological findings are resolved with the use of GEP test results.

Irregular papule with atypical histopathological findings and borderline/uncertain diagnosis

Jun 2023

Definitive diagnosis cannot be reached in an irregular, raised papule on the dorsal foot.

Atypical melanocytic proliferation on sensitive preauricular check

Jun 2023

Histopathological assessment of a melanocytic lesion on the check could not definitively rule out melanoma leading to the use of GEP prior to determining surgical management.

Routine imaging guided by a 31-gene expression profile assay results in earlier detection of melanoma with decreased metastatic tumor burden compared to patients without surveillance imaging studies

Mar 2023

Independent multi-center study demonstrates risk-aligned treatment plans guided by DecisionDx-Melanoma lead to better patient outcomes.

Author: Dhillon S, et al.

Publication: Archives of Derm Research

The 31-gene expression profile test informs sentinel lymph node biopsy decisions in patients with cutaneous melanoma: results of a prospective, multicenter study

Jan 2023

DecisionDx-Melanoma test results influenced 85% of clinicians’ decisions regarding the SLNB surgical procedure. Use of the test results could help avoid unnecessary procedures in low-risk patients whose tumor biology indicates they could safely forgo the procedure.

Author: Yamamoto M, et al.

Publication: Current Medical Research and Opinion

Incorporating prognostic gene expression profile assays into the management of cutaneous melanoma: an expert consensus panel report

Jan 2023

Expert panel of 6 key opinion leaders in dermatology consensus panel unanimously approved eleven usage guidelines and consensus supporting statements for the appropriate use of GEP testing.

Author: Zakria D, et al.

Publication: SKIN: Journal of Cutaneous Melanoma